Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 52Carcinoma, Non-Small-Cell Lung 29Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 24Stomach Neoplasms 19Recurrence 19Multiple Myeloma 19Neoplasm Metastasis 18Carcinoma, Hepatocellular 18Lung Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 12Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Esophageal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Doxorubicin 19Ifosfamide 12Radiotherapy 11pembrolizumab 6Nivolumab 6Ipilimumab 6pazopanib 4Specimen Handling 4Radiation 4Gemcitabine 4Docetaxel 4CTLA-4 Antigen 4Biopsy 4Trabectedin 3Sunitinib 3Magnetic Resonance Spectroscopy 3pegfilgrastim 2liposomal doxorubicin 2cabozantinib 2brostallicin 2X-Rays 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Methotrexate 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Diathermy 2Cisplatin 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Injections × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡